Literature DB >> 21233314

Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

James Marvin1, Suchitra Swaminathan, Geoffrey Kraker, Amy Chadburn, James Jacobberger, Charles Goolsby.   

Abstract

Molecular and cytogenetic alterations are involved in virtually every facet of acute myeloid leukemia (AML), including dysregulation of major signal-transduction pathways. The present study examines 5 phosphoproteins (pErk, pAkt, pS6, pStat3, and pStat5) in response to 5 cytokine/growth factors (stem cell factor [SCF], Flt-3/Flk-2 ligand [FL], granulocyte/macrophage-colony stimulating factor [GM-CSF], interleukin-3 [IL-3], and granulocyte-CSF [G-CSF]) within 7 immunophenotypically defined populations, spanning progenitor to mature myeloid/myelomonocytic cells in normal bone marrows with further comparison to AML samples. The normal cohort showed pathway-specific responses related to lineage, maturation, and stimulus. Heterogeneous-signaling responses were seen in homogeneous immunophenotypic subsets emphasizing the additive information of signaling. These profiles provided a critical baseline for detection of dysregulated signaling in AML falling into 4 broad categories, viz lack of response, increased activation, altered constitutive expression, and dysregulated response kinetics, easily identified in 10 of 12 AMLs. These studies clearly show robust and reproducible flow cytometry phosphoprotein analyses capable of detecting abnormal signal-transduction responses in AML potentially contributing to definitive reliable identification of abnormal cells. As functional correlates of underlying genetic abnormalities, signal-transduction abnormalities may provide more stable indicators of abnormal cells than immunophenotyping which frequently changes after therapy and disease recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233314      PMCID: PMC3087538          DOI: 10.1182/blood-2010-10-316026

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events.

Authors:  Peter O Krutzik; Garry P Nolan
Journal:  Cytometry A       Date:  2003-10       Impact factor: 4.355

Review 2.  Clinical flow cytometry: a transition in utilization.

Authors:  Charles L Goolsby; Mary Paniagua; Laura Marszalek
Journal:  Cancer Treat Res       Date:  2004

3.  JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor.

Authors:  D Linnekin; S R Weiler; S Mou; C S DeBerry; J R Keller; F W Ruscetti; D K Ferris; D L Longo
Journal:  Acta Haematol       Date:  1996       Impact factor: 2.195

4.  Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry.

Authors:  Pier Luigi Tazzari; Alessandra Cappellini; Tiziana Grafone; Irina Mantovani; Francesca Ricci; Anna Maria Billi; Emanuela Ottaviani; Roberto Conte; Giovanni Martinelli; Alberto M Martelli
Journal:  Br J Haematol       Date:  2004-09       Impact factor: 6.998

5.  Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome.

Authors:  June-Won Cheong; Ju In Eom; Ho-Young Maeng; Seung Tae Lee; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

6.  Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.

Authors:  James W Jacobberger; R Michael Sramkoski; Phyllis S Frisa; Peggy Peng Ye; Megan A Gottlieb; David W Hedley; T Vincent Shankey; Bradley L Smith; Mary Paniagua; Charles L Goolsby
Journal:  Cytometry A       Date:  2003-08       Impact factor: 4.355

Review 7.  Regulation of myeloid development and function by colony stimulating factors.

Authors:  Daniel R Barreda; Patrick C Hanington; Miodrag Belosevic
Journal:  Dev Comp Immunol       Date:  2004-05-03       Impact factor: 3.636

8.  JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor.

Authors:  S R Weiler; S Mou; C S DeBerry; J R Keller; F W Ruscetti; D K Ferris; D L Longo; D Linnekin
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

9.  JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region.

Authors:  F W Quelle; N Sato; B A Witthuhn; R C Inhorn; M Eder; A Miyajima; J D Griffin; J N Ihle
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

10.  Critical cytoplasmic domains of the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation.

Authors:  K Sakamaki; I Miyajima; T Kitamura; A Miyajima
Journal:  EMBO J       Date:  1992-10       Impact factor: 11.598

View more
  15 in total

1.  Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.

Authors:  Alexander E Perl; Margaret T Kasner; Doris Shank; Selina M Luger; Martin Carroll
Journal:  Clin Cancer Res       Date:  2011-12-13       Impact factor: 12.531

2.  miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.

Authors:  Amanda J Favreau; Pradeep Sathyanarayana
Journal:  Leuk Res       Date:  2011-10-19       Impact factor: 3.156

Review 3.  CREB and leukemogenesis.

Authors:  Er-Chieh Cho; Bryan Mitton; Kathleen M Sakamoto
Journal:  Crit Rev Oncog       Date:  2011

4.  High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.

Authors:  Philip G Woost; Luis A Solchaga; Howard J Meyerson; T Vincent Shankey; Charles L Goolsby; James W Jacobberger
Journal:  Blood       Date:  2011-02-17       Impact factor: 22.113

5.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  George S Laszlo; Rhonda E Ries; Chelsea J Gudgeon; Kimberly H Harrington; Todd A Alonzo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2014-03-24

6.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Authors:  Michele S Redell; Marcos J Ruiz; Robert B Gerbing; Todd A Alonzo; Beverly J Lange; David J Tweardy; Soheil Meshinchi
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

7.  Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Authors:  Ivana Gojo; Alexander Perl; Selina Luger; Maria R Baer; Kelly J Norsworthy; Kenneth S Bauer; Michael Tidwell; Stephanie Fleckinger; Martin Carroll; Edward A Sausville
Journal:  Invest New Drugs       Date:  2013-02-27       Impact factor: 3.850

8.  Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Authors:  Steven M Kornblau; Aileen C Cohen; David Soper; Ying-Wen Huang; Alessandra Cesano
Journal:  Cytometry B Clin Cytom       Date:  2013-09-16       Impact factor: 3.058

9.  Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine.

Authors:  Eleftheria Lamprianidou; Chryssoula Kordella; Anastasiya Kazachenka; Emmanouela Zoulia; Elsa Bernard; Anastasia Filia; Stamatia Laidou; Panayiotis Garantziotis; Theodoros P Vassilakopoulos; Sotirios G Papageorgiou; Vassiliki Pappa; Athanasios G Galanopoulos; Nora Viniou; Evangelia Nakou; Lydia Kalafati; Anastasia Chatzidimitriou; George Kassiotis; Elli Papaemmanuil; Ioannis Mitroulis; Ioannis Kotsianidis
Journal:  Blood Adv       Date:  2021-01-12

10.  RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1.

Authors:  K Liddiard; A K Burnett; R L Darley; A Tonks
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.